97 related articles for article (PubMed ID: 30243588)
21. Synthesis and antitumor activity of 20-O-linked nitrogen-based camptothecin ester derivatives.
Wang CY; Pan XD; Liu HY; Fu ZD; Wei XY; Yang LX
Bioorg Med Chem; 2004 Jul; 12(13):3657-62. PubMed ID: 15186850
[TBL] [Abstract][Full Text] [Related]
22. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.
Li GP; Zhang H; Zhu CM; Zhang J; Jiang XF
World J Gastroenterol; 2005 Oct; 11(40):6288-94. PubMed ID: 16419157
[TBL] [Abstract][Full Text] [Related]
23. Design of a bifunctional fusion protein for ovarian cancer drug delivery: single-chain anti-CA125 core-streptavidin fusion protein.
Wang WW; Das D; McQuarrie SA; Suresh MR
Eur J Pharm Biopharm; 2007 Mar; 65(3):398-405. PubMed ID: 17257818
[TBL] [Abstract][Full Text] [Related]
24. Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro.
Yellepeddi VK; Kumar A; Palakurthi S
Anticancer Res; 2009 Aug; 29(8):2933-43. PubMed ID: 19661298
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
Frapolli R; Zucchetti M; Sessa C; Marsoni S; Viganò L; Locatelli A; Rulli E; Compagnoni A; Bello E; Pisano C; Carminati P; D'Incalci M
Eur J Cancer; 2010 Feb; 46(3):505-16. PubMed ID: 20007015
[TBL] [Abstract][Full Text] [Related]
26. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
[TBL] [Abstract][Full Text] [Related]
27. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
[TBL] [Abstract][Full Text] [Related]
28. Ruthenium(II)-phenanthroline-biotin complexes: synthesis and luminescence enhancement upon binding to avidin.
Slim M; Sleiman HF
Bioconjug Chem; 2004; 15(5):949-53. PubMed ID: 15366946
[TBL] [Abstract][Full Text] [Related]
29. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
30. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
31. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Di Francesco AM; Riccardi A; Barone G; Rutella S; Meco D; Frapolli R; Zucchetti M; D'Incalci M; Pisano C; Carminati P; Riccardi R
Biochem Pharmacol; 2005 Oct; 70(8):1125-36. PubMed ID: 16139802
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of a biotinylated camptothecin derivative and determination of the binding sequence by T7 phage display technology.
Takakusagi Y; Ohta K; Kuramochi K; Morohashi K; Kobayashi S; Sakaguchi K; Sugawara F
Bioorg Med Chem Lett; 2005 Nov; 15(21):4846-9. PubMed ID: 16143529
[TBL] [Abstract][Full Text] [Related]
33. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
[TBL] [Abstract][Full Text] [Related]
34. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA
Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488
[TBL] [Abstract][Full Text] [Related]
35. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Rose WC; Marathe PH; Jang GR; Monticello TM; Balasubramanian BN; Long B; Fairchild CR; Wall ME; Wani MC
Cancer Chemother Pharmacol; 2006 Jul; 58(1):73-85. PubMed ID: 16228206
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
Wang Z; Sinha BK
Mol Pharmacol; 1996 Feb; 49(2):269-75. PubMed ID: 8632759
[TBL] [Abstract][Full Text] [Related]
38. Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9-NC.
Hu X; Balan KV; Ramos-DeSimone N; Wyche JH; Han Z; Pantazis P
Anticancer Drugs; 2003 Jul; 14(6):427-36. PubMed ID: 12853884
[TBL] [Abstract][Full Text] [Related]
39. A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability.
Rodríguez-Berna G; Mangas-Sanjuán V; Gonzalez-Alvarez M; Gonzalez-Alvarez I; García-Giménez JL; Díaz Cabañas MJ; Bermejo M; Corma A
Eur J Med Chem; 2014 Aug; 83():366-73. PubMed ID: 24980118
[TBL] [Abstract][Full Text] [Related]
40. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.
Yao Z; Zhang M; Kobayashi H; Sakahara H; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1995 May; 36(5):837-41. PubMed ID: 7738661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
